Besides, puromycin proved to promote the function of farnesiferol c in downregulating CCND1 and CDK4 in non-small-cell lung cancer cells [62], which not only supports the scientific hypothesis but also provides a new clue for LGG treatments. This evidence concerns the gene CDK4 and non-small cell lung carcinoma.